FDA approves Zepbound® (tirzepatide) as the first and only prescription medicine for moderate-to-severe obstructive sleep apnea in adults with obesity | Eli Lilly and Company
The Investor Relations website contains information about Eli Lilly and Company’s business for stockholders, potential investors, and financial analysts.